The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
Open accessAbstract
Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage–specific risk of all‐cause and liver‐related mortality in NAFLD. Through a systematic review and meta‐analysis, we identified five adult NAFLD cohort studies reporting fibrosis stage–specific mortality (0‐4). Using fibrosis stage 0 as a reference population, fibrosis stage–specific mortality rate ratios (MRRs) with 95% confidence intervals (CIs) for all‐cause and liver‐related mortality were estimated. The study is reported according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses statement. Included were 1,495 NAFLD patients with 17,452 patient years of follow‐up. Compared to NAFLD patients with no fibrosis (stage 0), NAFLD patients with fibrosis were at an increased risk for all‐cause mortality, and this risk increased with increases in the stage of fibrosis: stage 1, MRR = 1.58 (95% CI 1.19‐2.11); stage 2, MRR = 2.52 (95% CI 1.85‐3.42); stage 3, MRR = 3.48 (95% CI 2.51‐4.83); and stage 4, MRR = 6.40 (95% CI 4.11‐9.95). The results were more pronounced as the risk of liver‐related mortality increased exponentially with each increase in the stage of fibrosis: stage 1, MRR = 1.41 (95% CI 0.17‐11.95); stage 2, MRR = 9.57 (95% CI 1.67‐54.93); stage 3, MRR = 16.69 (95% CI 2.92‐95.36); and stage 4, MRR = 42.30 (95% CI 3.51‐510.34). Limitations of the study include an inability to adjust for comorbid conditions or demographics known to impact fibrosis progression in NAFLD and the inclusion of patients with simple steatosis and nonalcoholic steatohepatitis without fibrosis in the reference comparison group. Conclusion: The risk of liver‐related mortality increases exponentially with increase in fibrosis stage; these data have important implications in assessing the utility of each stage and benefits of regression of fibrosis from one stage to another. (H epatology 2017;65:1557‐1565).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The degree of liver fibrosis remains the most robust histological predictor of liver-related morbidity and mortality in patients with MASLD (Dulai et al. 2017).”
From The double-edged sword of regulatory T cells in MASLD: from inflammation control to fibrosis promotion (2026) · cites this paper as Dulai et al. 2017
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“prognosis is mostly influenced by the grade of fibrosis rather than presence/absence of NASH [9, 10].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“once a diagnosis of NASH and/or advanced fibrosis (i.e. fibrosis stage 3 or cirrhosis) and/or portal hypertension is confirmed patients are at an increased risk for liver‐related complications (i.e. hepatic decompensation and hepatocellular carcinoma) and liver‐related mortality [9, 10, 25].”
From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The progression to NASH involves hepatocyte damage and liver inflammation, with the development of liver fibrosis being the key determinant of patient outcomes 3-9 .”
From Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis (2024) · cites this paper as [6]
Experimental — accuracy not yet measuredIn the citing paper
“In patients with MASLD, liver fibrosis represents the primary determinant of mortality [258–261].”
From Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells (2025) · cites this paper as [259]
In the citing paper
“Among these features, the extent of fibrosis is the strongest predictor of patient mortality, and is therefore the focus of drug development efforts (13-16).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [16]
In the citing paper
“Such clinical observations, coupled with the knowledge that fibrosis is the most significant predictor of patient mortality in MASH, focus renewed attention on mechanisms of both spontaneous and pharmacologic-induced fibrosis regression (13-16), as more research is needed to develop clinical interventions that halt progression or reverse the disease.”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Stang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,854
Self-citationNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Self-citationAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Nonalcoholic Fatty Liver Disease
Rinella, M. E. (2015) · JAMA · doi:10.1001/jama.2015.5370 · Cited by 2,320
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stål, P., Kechagias, S., & Hultcrantz, R. (2015) · Hepatology · doi:10.1002/hep.27368 · Cited by 2,287
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 801–900 of 1,004
Identifying High-Risk NASH Patients: What We Know so Far
Schulz, M., & Tacke, F. (2020) · Hepatic Medicine Evidence and Research · doi:10.2147/hmer.s265473 · Cited by 21
Paternostro, R., Becker, J., Hofer, B. S., Panagl, V., Schiffke, H., Simbrunner, B., Semmler, G., Schwabl, P., Scheiner, B., Bucsics, T., et al. (2022) · Digestive and Liver Disease · doi:10.1016/j.dld.2021.09.009 · Cited by 17
Alsaqal, S., Hockings, P. D., Ahlström, H. K., Gummesson, A., Hedström, A., Hulthe, J., Johansson, L., Niessen, H. G., Schoelch, C., Schultheis, C., et al. (2021) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.28040 · Cited by 22
Nabi, O., Boursier, J., Lapidus, N., Mathurin, P., de Lédinghen, V., Petit, J., Goldberg, M., Zins, M., Lacombe, K., & Serfaty, L. (2022) · Liver International · doi:10.1111/liv.15171 · Cited by 21
Liver Fibrosis Marker and Postoperative Mortality in Patients Without Overt Liver Disease
Zelber‐Sagi, S., O’Reilly-Shah, V. N., Fong, C. T., Wajcman, D. I., Reed, M. J., & Bentov, I. (2022) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000006044 · Cited by 21
Zhang, M., Tian, S. Y., Shuo, Y., Zhou, X., Zheng, X. H., Li, B., Guo, G. Y., Yu, J. H., Su, R. J., Yang, F. F., et al. (2023) · Liver International · doi:10.1111/liv.15547 · Cited by 22
Bertot, L. C., Jeffrey, G. P., de Boer, B., Wang, Z., Huang, Y., Garas, G., MacQuillan, G. C., Wallace, M., Smith, B. W., & Adams, L. A. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-023-07896-3 · Cited by 21
Sako, S., Takeshita, Y., Takayama, H., Goto, H., Nakano, Y., Ando, H., Tsujiguchi, H., Yamashita, T., Arai, K., Kaneko, S., et al. (2023) · Diabetes · doi:10.2337/db22-0933 · Cited by 22
Xu, X., Jin, J., & Liu, Y. (2023) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2023.08.003 · Cited by 21
Schwenger, K. J. P., Sharma, D., Ghorbani, Y., Xu, W., Lou, W. Y. W., Comelli, E. M., Fischer, S. E., Jackson, T. D., Okrainec, A., & Allard, J. P. (2024) · Liver International · doi:10.1111/liv.15864 · Cited by 22
Käräjämäki, A. J., Hukkanen, J., Kauma, H., Kesäniemi, Y. A., & Ukkola, O. H. (2019) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2019.1700428 · Cited by 22
Kao, W., Chang, I., Chen, C., Su, C., Fang, S. U., Tang, J., Chang, C., Chang, Y., & Wang, W. (2020) · Obesity Surgery · doi:10.1007/s11695-019-04192-w · Cited by 21
Wongtrakul, W., Niltwat, S., Charatcharoenwitthaya, N., Karaketklang, K., & Charatcharoenwitthaya, P. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16666 · Cited by 23
Cathcart, J., Barrett, R., Bowness, J. S., Mukhopadhya, A., Lynch, R., & Dillon, J. F. (2024) · Liver International · doi:10.1111/liv.16127 · Cited by 20
Mino, M., Kakazu, E., Sano, A., Tsuruoka, M., Matsubara, H., Kakisaka, K., Kogure, T., Sekine, K., Aoki, Y., Imamura, M., et al. (2024) · Amino Acids · doi:10.1007/s00726-024-03433-2 · Cited by 20
Resmetirom: the first approved therapy for treating metabolic dysfunction associated steatohepatitis
Bhushan, S. R., Sohal, A., Noureddin, M., & Kowdley, K. V. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2478917 · Cited by 20
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 23
Li, J., Qureshi, M. M., Gupta, A., Anderson, S. W., Soto, J. A., & Li, B. (2018) · Academic Radiology · doi:10.1016/j.acra.2018.10.004 · Cited by 20
Fatty liver, cardiometabolic disease and mortality
Bedogni, G., Gastaldelli, A., & Foschi, F. G. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000652 · Cited by 21
Pennisi, G., Marco, V. D., Buscemi, C., Mazzola, G. C., Randazzo, C., Spatola, F., Craxı̀, A., Buscemi, S., & Petta, S. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15523 · Cited by 22
Gabriel-Medina, P., Ferrer, R., Rodríguez‐Frias, F., Ciudin, A., Augustín, S., Rivera‐Esteban, J., Pericàs, J. M., & Selva, D. M. (2022) · Biomedicines · doi:10.3390/biomedicines10051015 · Cited by 20
One-hour post-load glucose is associated with severity of hepatic fibrosis risk
Jagannathan, R., Fiorentino, T. V., Marini, M. A., Sesti, G., & Bergman, M. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109977 · Cited by 20
Ancestral BPA exposure caused defects in the liver of medaka for four generations
Chakraborty, S., Dissanayake, M., Godwin, J., Wang, X., & Bhandari, R. K. (2022) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2022.159067 · Cited by 22
Bril, F., Pearce, R. W., Collier, T. S., & McPhaul, M. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac565 · Cited by 21
Ultrasound Radiomics for the Detection of Early-Stage Liver Fibrosis
Al‐Hasani, M., Sultan, L. R., Sagreiya, H., Cary, T. W., Karmacharya, M. B., & Sehgal, C. M. (2022) · Diagnostics · doi:10.3390/diagnostics12112737 · Cited by 21
Nonalcoholic fatty liver disease (NAFLD) among older adults
Pitisuttithum, P., & Treeprasertsuk, S. (2022) · Portal hypertension & cirrhosis · doi:10.1002/poh2.31 · Cited by 20
Sato, M., Akamatsu, M., Shima, T., Ikegami, T., Yanase, M., Mikami, S., Imamura, J., Nakatsuka, T., Tateishi, R., Yamauchi, N., et al. (2022) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002143 · Cited by 20
Sheng, X., Zhan, P., Wang, P., He, W., & Tian, H. (2024) · Food & Function · doi:10.1039/d3fo05235d · Cited by 20
Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
Sayıner, M., Lam, B. P., Golabi, P., & Younossi, Z. M. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818811508 · Cited by 20
Self-citationRepurposing drugs to target nonalcoholic steatohepatitis
Sookoian, S., & Pirola, C. J. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i15.1783 · Cited by 20
Auguet, T., Bertran, L., Binetti, J., Aguilar, C., Martínez, S., Guiu‐Jurado, E., Sabench, F., Adalid, L., Porras, J. A., Riesco, D., et al. (2020) · Obesity · doi:10.1002/oby.22873 · Cited by 20
Lupșor‐Platon, M., Serban, T., Silion, A. I., Tirpe, A., & Florea, M. (2020) · Cancers · doi:10.3390/cancers12102778 · Cited by 20
Yamada, G., Hagiwara, Y., Kimura, T., Takeuchi, Y., Oba, K., Masuda, K., & Matsuyama, Y. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001030 · Cited by 20
Tamaki, N., Munaganuru, N., Jung, J., Yonan, A. Q., Bettencourt, R., Ajmera, V. H., Valasek, M. A., Behling, C. A., & Loomba, R. S. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.11.005 · Cited by 20
Self-citationYounossi, Z. M., Pham, H., Felix, S. C., Stepanova, M., Jeffers, T., Younossi, E., Allawi, H., Lam, B. P., Cable, R., Afendy, M., et al. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000340 · Cited by 20
Self-citationMazzini, G. S., Augustin, T., Noria, S. F., Romero‐Marrero, C., Li, N., Hameed, B., Eisenberg, D., Azagury, D. E., & Ikramuddin, S. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.11.015 · Cited by 20
Stine, J. G., Schreibman, I., Navabi, S., Kang, M., Dahmus, J., Soriano, C., Rivas, G., Hummer, B., Beyer, M., Tressler, H., et al. (2020) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2020.100560 · Cited by 19
Dual Role of Pregnane X Receptor in Nonalcoholic Fatty Liver Disease
Xu, Y., An, Z., Wang, S., Ni, Y., Zhou, M., Feng, Q., Gou, X., Xu, M., & Qi, Y. (2023) · Current Molecular Pharmacology · doi:10.2174/0118761429259143230927110556 · Cited by 19
Kang, Y. W., Baek, Y. H., & Moon, S. Y. (2024) · Diagnostics · doi:10.3390/diagnostics14222517 · Cited by 19
Luthra, R., & Sheth, A. (2024) · Advances in Therapy · doi:10.1007/s12325-024-03085-4 · Cited by 21
Engineered Hydrogels for Organoid Models of Human Nonalcoholic Fatty Liver Disease
Liu, Y., Gilchrist, A. E., Johansson, P. K., Guan, Y., Deras, J. D., Liu, Y., Ceva, S., Huang, M. S., Navarro, R. S., Enejder, A. M. K., et al. (2025) · Advanced Science · doi:10.1002/advs.202417332 · Cited by 22
Younossi, Z. M., Paik, J. M., Lazarus, J. V., Burra, P., Eguchi, Y., Tacke, F., Crespo, J., Villela‐Nogueira, C. A., Brennan, P., Al‐Omar, H. A., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.09.002 · Cited by 22
Self-citationDepletion of Bone Marrow-Derived Fibrocytes Attenuates TAA-Induced Liver Fibrosis in Mice
Hempel, F., Roderfeld, M., Savai, R., Sydykov, A. S., Irungbam, K., SCHERMULY, R. T., Voswinckel, R., Köhler, K., Churin, Y., Kiss, L., et al. (2019) · Cells · doi:10.3390/cells8101210 · Cited by 19
Presumed Nonalcoholic Fatty Liver Disease Among Medicare Beneficiaries With HIV, 2006–2016
Paik, J. M., Henry, L. L., Golabi, P., Alqahtani, S. A., Trimble, G., & Younossi, Z. M. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofz509 · Cited by 19
Self-citationNitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH
Maeda, H., Ishima, Y., Saruwatari, J., Mizuta, Y., Minayoshi, Y., Ichimizu, S., Yanagisawa, H., Nagasaki, T., Yasuda, K., Oshiro, S., et al. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.039 · Cited by 22
Ben‐Assuli, O., Jacobi, A., Goldman, O., Shenhar‐Tsarfaty, S., Rogowski, O., Zeltser, D., Shapira, I., Berliner, S. A., & Zelber‐Sagi, S. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.103986 · Cited by 18
RNA binding protein HuR protects against NAFLD by suppressing long noncoding RNA H19 expression
Wang, Y., Tai, Y., Way, G. W., Zeng, J., Zhao, D., Su, L., Jiang, X., Jackson, K. G., Wang, X., Gurley, E. C., et al. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00910-7 · Cited by 19
Park, H., Yoon, E. L., Kim, M., Lee, J., Cho, S., Jun, D. W., & Nah, E. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1024836 · Cited by 19
Kugelmas, M., Noureddin, M., Gunn, N., Brown, K., Younossi, Z. M., Abdelmalek, M. F., & Alkhouri, N. (2023) · Liver International · doi:10.1111/liv.15555 · Cited by 18
Self-citationNabi, O., Lapidus, N., Boursier, J., de Lédinghen, V., Kab, S., Renuy, A., Zins, M., Serfaty, L., & Lacombe, K. (2023) · Liver International · doi:10.1111/liv.15674 · Cited by 19
Alkhouri, N., Lazas, D. J., Loomba, R. S., Frías, J. P., Feng, S., Tseng, L., Balic, K., Agollah, G. D., Kwan, T., Iyer, J. S., et al. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17709 · Cited by 19
Self-citationTincopa, M. A., Díaz, L. A., Huang, D. Q., Arab, J. P., Arrese, M. A., Gadano, A., de Oliveira, C. P. M. S., Bettencourt, R., Madamba, E. V., Kim, S., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000001121 · Cited by 20
Self-citationAtsukawa, M., Tsubota, A., Okubo, T., Arai, T., Nakagawa, A., Itokawa, N., Kondo, C., Kato, K., Hatori, T., Hano, H., et al. (2017) · Hepatology Research · doi:10.1111/hepr.13046 · Cited by 19
Augustín, S., Ahmed, A., Alkhouri, N., Canbay, A. E., Corless, L., Nakajima, A., Okanoue, T., Petta, S., Ratziu, V., Tsochatzis, E. A., et al. (2020) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-775 · Cited by 19
Self-citationShima, T., Ohtakaki, Y., Kikuchi, H., Uchino, H., Isomura, M., Aoyagi, K., Oya, H., Katayama, T., Mitsumoto, Y., Mizuno, M., et al. (2020) · Hepatology Research · doi:10.1111/hepr.13605 · Cited by 19
Leite, N. C., Cardoso, C. R. L., & Salles, G. F. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107879 · Cited by 19
Du, J., Chai, S., Zhao, X., Sun, J., Zhang, X., & Huo, L. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313503 · Cited by 19
Management of NAFLD patients with advanced fibrosis
Maya‐Miles, D., Ampuero, J., Gallego‐Durán, R., D’Ingianna, P., & Romero‐Gómez, M. (2021) · Liver International · doi:10.1111/liv.14847 · Cited by 19
Decraecker, M., Dutartre, D., Hiriart, J., Irlès‐Depé, M., Chermak, F., Foucher, J., & de Lédinghen, V. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16760 · Cited by 19
Adinolfi, L. E., Marrone, A., Rinaldi, L., Nevola, R., Izzi, A., & Sasso, F. C. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001281 · Cited by 18
Amin, M. A., Sadik, N. A., Saad, H. A., Fawzy, M., & Elsheimy, H. A. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03902-w · Cited by 21
Ng, W. H., Yeo, Y. H., Kim, H., Seki, E., Rees, J. R. E., Sheng‐Kai, K., Moylan, C. A., Rodriguez, L. M., Abdelmalek, M. F., Villanueva, A., et al. (2025) · Hepatology · doi:10.1097/hep.0000000000001333 · Cited by 19
Díaz, L. A., Tavaglione, F., Mittal, N., Bettencourt, R., Amangurbanova, M., Johnson, A., Aguado, D. M., Tincopa, M. A., Loomba, R. K., Khan-Riches, A., et al. (2025) · Hepatology Communications · doi:10.1097/hc9.0000000000000718 · Cited by 19
Self-citationNonalcoholic Fatty Liver Disease and Mortality
Stefan, N. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.02.016 · Cited by 18
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Obesity · doi:10.1002/oby.23250 · Cited by 18
Self-citationAl‐Omary, A., Byth, K., Weltman, M., George, J., & Eslam, M. (2021) · Journal of Digestive Diseases · doi:10.1111/1751-2980.13071 · Cited by 18
Ma, Q., Ye, J., Shao, C., Lin, Y., Wu, T., & Zhong, B. (2022) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188221122426 · Cited by 19
Waller, K., Saihi, H., Li, W., Brindley, J. H., Jong, A. D., Syn, W., Bessant, C., & Alazawi, W. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0205 · Cited by 18
Research Priorities for Precision Medicine in NAFLD
Iruzubieta, P., Bataller, R. A., Arias, M., Arrese, M. A., Calleja, J. L., Castro‐Narro, G., Cusi, K. J., Dillon, J. F., Martínez‐Chantar, M. L., Mateo, M., et al. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.016 · Cited by 18
Nakamura, S., Nakamura, K., Yokoi, Y., Shimizu, Y., Ohira, S., Hagiwara, M., Song, Z., Gan, L. H., Aizawa, T., Hashimoto, D., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30997-y · Cited by 18
Zhong, X., Lv, M., Ma, M., Huang, Q., Hu, R., Li, J., Yi, J., Sun, J., & Zhou, X. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115131 · Cited by 20
Saldarriaga, Ó. A., Wanninger, T. G., Arroyave, E., Gosnell, J., Krishnan, S., Oneka, M. D., Bao, D., Millian, D. E., Kueht, M., Moghe, A., et al. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100958 · Cited by 21
Zhang, F., Han, Y., Wu, Y., Bao, Z., Zheng, G., Liu, J., & Li, W. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2409342 · Cited by 20
Longitudinal Evaluation of Individuals With Severe Alpha-1 Antitrypsin Deficiency (Pi∗ZZ Genotype)
Fromme, M., Payancé, A., Mandorfer, M., Thorhauge, K. H., Pons, M., Miravitlles, M., Stolk, J. N., van Hoek, B., Stirnimann, G., Fraňková, S., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.10.010 · Cited by 19
Muralidharan, S., Lee, J. W. J., Lim, Y. S., Muthiah, M. D., Tan, E., Demicioglu, D., Shabbir, A., Loo, W. M., Koo, C. S., Lee, Y. M., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156063 · Cited by 18
Mikolašević, I., Domislović, V., Klapan, M., Jurić, T., Lukic, A., Zrnić, I. K., Čupić, D. F., Štimac, D., Kanižaj, T. F., Krznarić, Ž., et al. (2021) · Ultrasound in Medicine & Biology · doi:10.1016/j.ultrasmedbio.2020.11.015 · Cited by 18
Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand
Phisalprapa, P., Prasitwarachot, R., Kositamongkol, C., Hengswat, P., Srivanichakorn, W., Washirasaksiri, C., Treeprasertsuk, S., Charatcharoenwitthaya, P., & Chaiyakunapruk, N. (2021) · BMC Gastroenterology · doi:10.1186/s12876-021-01720-w · Cited by 18
Hardesty, J., Wahlang, B., Prough, R. A., Head, K. Z., Wilkey, D. W., Merchant, M. L., Shi, H., Jin, J., & Cave, M. C. (2021) · Environmental Health Perspectives · doi:10.1289/ehp8222 · Cited by 18
Kakegawa, T., Sugimoto, K., Kuroda, H., Suzuki, Y., Imajo, K., Toyoda, H., Tamaki, N., Yasuda, S., Yasui, Y., Kurosaki, M., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.08.021 · Cited by 18
The Mitochondrial Trigger in an Animal Model of Nonalcoholic Fatty Liver Disease
Chimienti, G., Orlando, A., Russo, F., D’Attoma, B., Aragno, M., Aimaretti, E., Lezza, A. M. S., & Pesce, V. (2021) · Genes · doi:10.3390/genes12091439 · Cited by 21
Dobbie, L. J., Kassab, M., Davison, A., Grace, P., Cuthbertson, D. J., & Hydes, T. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245755 · Cited by 18
Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis
Shi, Y., & Fan, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00822-1 · Cited by 19
Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist
Brunt, E. M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.08.014 · Cited by 19
Gawrieh, S., Adams, K. H., Pike, F., Yates, K. P., Wilson, L., Cummings, O. W., Rosenberg, W. M., Chalasani, N., & Molleston, J. P. (2021) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2021.08.012 · Cited by 17
Safran, M., Masoud, R., Sultan, M., Tachlytski, I., Gadot, C. C., Pery, R., Balint‐Lahat, N., Pappo, O., Buzaglo, N., & Ben‐Ari, Z. (2022) · Cells · doi:10.3390/cells11101715 · Cited by 17
Yilmaz, Y. N., Toraman, A. E., Alp, C., Doğan, Z., Keklikkıran, Ç., Stepanova, M., & Younossi, Z. M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17301 · Cited by 17
Self-citationCernea, S., & Onișor, D. M. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i2.286 · Cited by 18
Tapper, E. B., Bonafede, M., Fishman, J., Dodge, S., Miller, K., Zeng, N., Lewandowski, D., & Bogdanov, A. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2184967 · Cited by 17
Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms
Mitten, E. K., Portincasa, P., & Baffy, G. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2023.00029 · Cited by 17
Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies
Agyapong, G., Dashti, F., & Banini, B. A. (2023) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15012 · Cited by 18
Xing, Y., Gao, X., Li, Q., Li, X., Wang, Y., Yang, Y., Yang, S., Lau, P. W. C., Zeng, Q., & Wang, H. (2023) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2023.132501 · Cited by 17
Hirooka, M., Ogawa, S., Koizumi, Y., Yoshida, Y., Goto, T., Yasuda, S., Yamahira, M., Tamai, T., Kuromatsu, R., Matsuzaki, T., et al. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02096-w · Cited by 18
Patel, V., Mahmood, S., Bhatt, K., Khemkar, R. M., Jariwala, D., Harris, B., George, M. M., Kurudamannil, R. A., Anyagwa, O. E., Tak, R. S., et al. (2024) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1434 · Cited by 21
Iruzubieta, P., Mayo, R., Mincholé, I., Martínez‐Arranz, I., Arias‐Loste, M. T., Ibáñez, L., Ampuero, J., Abad, J., Martín‐Mateos, R., Laso, A. B. F., et al. (2024) · United European Gastroenterology Journal · doi:10.1002/ueg2.12589 · Cited by 17
Mathur, A., Ozkaya, E., Rosberger, S., Sigel, K. M., Doucette, J. T., Bansal, M. B., & Taouli, B. A. (2025) · European Radiology · doi:10.1007/s00330-025-11533-0 · Cited by 17
Reversal of NASH fibrosis with pharmacotherapy
Alukal, J. J., & Thuluvath, P. J. (2019) · Hepatology International · doi:10.1007/s12072-019-09970-3 · Cited by 17
Niriella, M. A., Kasturiratne, A., Beddage, T., Withanage, S. A., Goonatilleke, D. C., Abeysinghe, C. P., Mel, R. T. D., Balapitiya, T. L., Silva, S. D., Dassanayake, A. S., et al. (2019) · Liver International · doi:10.1111/liv.14237 · Cited by 17
NAFLD Histology: a Critical Review and Comparison of Scoring Systems
Pai, R. K. (2019) · Current Hepatology Reports · doi:10.1007/s11901-019-00500-1 · Cited by 17
Noninvasive assessment of hepatic steatosis and fibrosis in patients with severe obesity
Coccia, F., Testa, M., Guarisco, G., Bonci, E., Cristofano, C. D., Silecchia, G., Leonetti, F., Gastaldelli, A., & Capoccia, D. (2019) · Endocrine · doi:10.1007/s12020-019-02155-w · Cited by 17
Roy, S. (2020) · Case Reports in Medicine · doi:10.1155/2020/4287075 · Cited by 17
Metadata
- Authors
- Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., Stal, P., Wong, V. W., Kechagias, S., Hultcrantz, R., & Loomba, R.
- Affiliations
- University of California San Diego (US)
- Mayo Clinic (US)
- Inova Fairfax Hospital (US)
- McGill University Health Centre (CA)
- Linköping University (SE)
- Department of Gastroenterology and Hepatology,Karolinska University Hospital, Karolinska Institutet,Stockholm,Sweden
- Karolinska University Hospital (SE)
- Chinese University of Hong Kong (HK)
- Corresponding author
- Loomba, Rohit
- ORCID
- Venue
- Hepatology
- Published
- 2017-03-31
- Volume
- 65
- Issue
- 5
- Pages
- 1557-1565
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- PMC
- PMC5397356
- OpenAlex
- W2580009538
- Cited by
- 1,965
- References
- 23
- Citations by year
- 2026: 199 · 2025: 193 · 2024: 227 · 2023: 263 · 2022: 240 · 2021: 272 · 2020: 249 · 2019: 163 · 2018: 101 · 2017: 48
- FWCI
- 20.15
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Gilead Sciences
- American Gastroenterological Association (R01‐DK106419, K23DK090303, 5T32DK007202)
- National Institutes of Health
- Fonds de Recherche du Québec - Santé
- National Institute of Diabetes and Digestive and Kidney Diseases (DK090303, R01DK106419, T32DK007202, K23DK090303)
- National Institute of Environmental Health Sciences (P42ES010337)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- non-alcoholic fatty liver disease, liver fibrosis, fibrosis stage, mortality risk, all-cause mortality, liver-related mortality, NAFLD progression, simple steatosis, nonalcoholic steatohepatitis, comorbidities, mortality prediction model, liver cancer, liver cirrhosis
- MeSH terms
- Fibrosis, Humans, Liver, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
